KLAS: Vendors struggling to deliver robust analytics products

Laura Pedulli | | Health Exec | Economics

Healthcare providers report that vendors are struggling to deliver user-friendly and robust healthcare analytics products, according to KLAS Enterprises.

According to its report, “Healthcare Analytics: Making Sense of the Puzzle Pieces,” there remains a persistent gap between what vendors deliver and what providers need at a time when analytics is seen as the cornerstone of new value-based models of care. KLAS interviewed more than 400 healthcare providers to capture their experiences with a number of business intelligence (BI) vendor products.

“Providers see analytics as a strategic compass for the changing healthcare world ahead, and their need for better results and better ways to understand outcomes through data analytics and BI is critical,” said Joe Van De Graaff, KLAS research director and report author.

More information about this study is available here.

Laura Pedulli

Related Content

Bill to regulate healthcare private equity lands on desk of Mass. governor
Mayo Clinic sues insurer over patient’s $740K in medical bills
The biggest challenges facing radiology business managers in 2025
Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.